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Pl antar fasciitis is the most common cause of chronic heel pain, observed in up to 10% of the general population. 1 Approximately 10% of all cases are considered refractory to medical treatment. 2 The condition is a major health issue in long-distance walkers, possibly caused by overuse injury, leading to repetitive microtears of the plantar fascia near the calcaneus. It is usually precipitated by a change in the individual's activity level or training program. Biomechanical factors also play an important role. The mainstay of all treatment strategies for plantar fasciitis first includes simple measures such as application of ice and heel cups, orthosis, activity modification, and a stretching/strengthening exercise program. Further measures include deep-tissue massage therapy, night splints, and periods of immobilization. Persistent cases may respond to treatment with posterior night splints, ultrasound, iontophoresis, phonophoresis, extracorporal shock therapy, or even local corticosteroid injections. 3 In cases of medical failures, surgery is advocated, with modest results. 4 There is a need for new treatment avenues, especially for refractory cases.
Over the last several years, botulinum toxin A (BTX-A) has been increasingly used in the treatment of various medical conditions. 5 Increasing literature supports the role of BTX-A in the treatment of chronic pain syndromes such as myofascial pain 6 -10 and refractory headaches. 11, 12 Although blockade of acetylcholine release from presynaptic vesicles 13 plays an important role in relief of muscle spasms and pain in myofascial syndromes, a number of animal studies, some of them recent, suggest alternative mechanisms for analgesic effects of this agent.
14 -18 Some of these mechanisms, antiinflammatory action and action against locally accumulated stimulant neurotransmitters (glutamate, substance P), 16 pertain to the pathophysiology of plantar fasciitis.
Encouraged by this literature, we conducted a prospective, randomized, double-blinded, placebocontrolled study examining the use of BTX-A in the treatment of refractory plantar fasciitis. To our knowledge, this is the first report on the use of BTX-A for this condition.
METHODS AND DESIGN
A prospective, randomized, double-blinded, placebo-controlled study was conducted comparing the effects of BTX-A injection with placebo (saline) in patients with plantar fasciitis. The inclusion criteria consisted of being an adult, a diagnosis of plantar fasciitis, duration of symptoms beyond 6 mos, and failure of conventional treatment strategies. Exclusion criteria consisted of an age of Ͻ18 yrs, any disease of the neuromuscular junction, and a history of hypersensitivity to BTX-A. Other exclusions consisted of an open wound of the foot or heel, history of foot surgery or fracture, or history of chronic narcotic use for any reason. In addition, patients with a physical examination consistent with fibromyalgia, nerve entrapment, radiculopathy, peripheral vascular disease, or decreased sensation of the foot or ankle were also excluded from the study. All women of childbearing age were required to have a negative pregnancy examination.
Plantar fasciitis was clinically defined as heel tenderness of gradual onset, localized to the medial process of the calcaneal tuberosity and exacerbated by weightbearing. 19, 20 The patients had almost all of the aforementioned therapeutic measures, with the exception of extracorporeal shock or surgery. The study was designed to recruit 60 patients. Due to the somewhat painful nature of the study, our institutional review board recommended an interim analysis to be performed if we see notable (more than double) response differences between the two groups. Our statistician recommended this to be performed after enrolling 25-30 patients (i.e., close to or at the midpoint of enrollment). Male and female participants were recruited, between the ages of 18 and 75 yrs, who met both inclusion and exclusion criteria. Patients with bilateral symptoms were included in the study and were randomly assigned BTX-A in one foot and placebo in the other. Participants and physicians were blinded to the agent that was injected. All randomization, data collection, and syringe preparation was performed by the same clinical research nurse, who maintained complete confidentiality and was not involved in patient rating. Block randomization was performed using computer-generated software provided by the Department of Clinical Investigation.
After receiving informed consent, each affected foot was randomized into either the BTX-A treatment group A or the placebo group B. The solution of BTX-A (BOTOX, Allergan, Irvine, CA) was prepared by mixing 100 units with 1 ml of normal saline. We injected the patients of group A with 70 units of BTX-A (0.7 ml) in two divided doses: 40 units (0.4 ml) in the tender region of the heel medial to the base of the plantar fascia insertion and 30 units (0.3 ml) in the most tender point of the arch of the foot (between an inch anterior to the heel to the middle of the foot) ( Fig. 1) . A 27-gauge, 0.75-inch needle was used for injections. Group B received normal saline at the same locations and of similar volume. In patients with bilateral plantar fasciitis of comparable severity, BTX-A was injected in one and saline in the other foot. All patients were also given a handout reviewing a home stretching program targeting the plantar fascia and gastroc/soleus muscle complex. No medication changes were recommended; however, patients were informed that receiving another injection or surgery on their foot would terminate their participation in the study.
Outcome Variables Included
The Pain Visual Analog Scale consists of a 10-cm line with the ends labeled "no pain" or "worst pain ever." Retest reliability with literate patients has been found to be 0.94. Regarding validity, correlations between vertical and horizontal Visual Analog Scales were approximately 0.89 -0.91. This study incorporated the horizontal scale. 21 Patients were asked to rate each affected foot preinjection and at 3 and 8 wks postinjection.
The pressure algometry response quantitatively assesses muscle tenderness at the site of the plantar fascial insertion. The device was positioned directly perpendicular to the sole of the foot, and incremental cutaneous pressures were slowly applied over the described areas. The average pressure of three serial measurements at which the subject first reported pain was recorded in kilograms. 22 All correlations of within-experimenter reliability and between-experimenter reliability were highly significant (P Ͻ 0.01). 23 Measurements were obtained preinjection and at 3 and 8 wks postinjection.
The Maryland Foot Score, developed by the Painful Foot Center at the University of Maryland, is based on a 100-point scale (excellent, 90 -100; good, 75-89; fair, 51-74; failure, Ͻ50) that assesses foot pain and function in relation to pain, gait, stability, support, limp, motion, and ability to climb stairs. 24 Although clinometric studies have not been conducted, the Maryland Foot Score has been found to be a valid test for pain and physical function. 25 The questionnaire for the Maryland Foot Score was administered by the physician preinjection and at 3 and 8 wks postinjection.
The Pain Relief Visual Analog Scale consists of a 10-cm line with the ends labeled "no relief" or "complete relief" of symptoms. According to the literature, because the initial and subsequent pain ratings tend to be correlated (coefficients of 0.62 and 0.63), a Pain Relief Visual Analog Scale is more advantageous than just comparing Pain Visual Analog Scale scores before and after treatment. 26, 27 Patients were asked to rate each affected foot at 3 and 8 wks postinjection.
The first three measures were considered our primary outcome measures. An improvement of Ն30% is considered for Visual Analog Scale and pressure algometry response, and an advancement to the next category (for example, fair to good, good to excellent) was considered significant for the Maryland Foot Score.
Statistical Analysis
The statistician assigned to the study indicated that to detect a difference of 35% response to pain between the BTX-A group (assumed 50%) and placebo group (assumed 15%) with an 85% confidence interval, 60 patients needed to be studied. Assuming an anticipated drop-out rate of 15%, we therefore set 
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Treatment of Pain in Plantar Fasciitis out to recruit patients. Change over time within a group was analyzed using Wilcoxon's signed-ranks test, and differences between groups were analyzed using Wilcoxon's rank-sum test. Statistical significance was set at P Ͻ 0.025 for the interim analysis and P Ͻ 0.05 for the final analysis. The statistical software package utilized was SPSS vs. 12 (SPSS, Chicago, IL).
RESULTS
At the time of interim analysis (8 wks after treatment), a total of 43 feet were studied from 27 subjects. Initial and 3-wk data existed on all feet. Seven patients did not report at 8 wks. Patients lost to follow-up (seven patients) were included in 8-wk statistical analyses as nonresponders. There were 22 feet in group A (BTX-A) and 21 feet in group B (placebo). The age of participants ranged from 21 to 65 yrs, with a median age of 44 yrs. The majority of patients were white, 18 followed by African American, 6 and then Asian or Hispanic. 3 Subjects with both unilateral and bilateral symptoms were included in the study. There were a total of 18 women (12 bilateral, six unilateral) and nine men (four bilateral, five unilateral) enrolled in the study. Group A consisted of 15 feet from female subjects and six feet from male subjects. Group B consisted of 15 feet from female subjects and seven feet from male subjects ( Table 1) . Bilateral symptoms were noted in 16 and unilateral symptoms in 11 patients. Of 16 bilateral patients, 12 improved on all outcome measures in the BTX-A-treated foot, and only one patient improved in the placebo-treated foot.
Compared with placebo, the BTX-A group manifested statistically significant results at 3 wks, with a 39% decrease on the Pain Visual Analog Scale, a 34% improvement of the Maryland Foot Score, and a 40% increase in pressure algometry response, with P values of Ͻ0.005, 0.001, and 0.003, respectively (Figs.  2-4) . The Pain Relief Visual Analog Scale was also significant, with a P value of Ͻ0.005. The placebo group had a 2.7% worsening on the Pain Visual Analog Scale, Ͻ0.01% improvement on the Maryland Foot Score, and Ͻ0.01% improvement on pressure algometry response.
At 8 wks, a total of 30 feet from 20 subjects were analyzed. A total of 13 feet from seven subjects were lost to follow-up because of changes in geographic location but were included in the analyses as nonresponders. The BTX-A group, consisting of 15 feet, 
FIGURE 2 Pain Visual Analog Scale scores for the botulinum toxin A (BTX-A) and placebo groups.
continued to show significant improvement in all variables, with a 56% decrease on the Pain Visual Analog Scale, a 47% increase on the Maryland Foot Score, and a 56% increase in pressure algometry response, with P values of Ͻ0.005, 0.001, and 0.003, respectively. The improvement on the Pain Relief Visual Analog Scale was also significant when compared with the placebo group (P value of Ͻ0.005). No known complications were noted in persons who maintained follow-up.
DISCUSSION
Plantar fascia is composed of dense collagen fibers that extend longitudinally from the calcaneus to the base of each proximal phalanx. The fascia has a medial, central, and lateral part, underneath which lies the abductor hallucis, flexor digitorum brevis, and flexor digiti minimi muscles, respectively. It holds down muscles and tendons in the concave surface of the sole and digits, facilitates excursion of the tendons, prevents excessive compression of digital vessels and nerves, and possibly aids in venous return. 28 A number of anatomic changes have been described in plantar fasciitis. These include marked thickening of the plantar fascia as demonstrated by several sonographic studies, 29 microtears related to repeated trauma, and secondary inflammatory changes. The pain in plantar fasciitis may be due to one or more of the following mechanisms: irritation of pain fibers by repeated trauma or chronic pressure from a thickened plantar fascia, 30 ischemic pain from chronic pressure of thickened fascia against digital vessels, enhanced effect of local pain neurotransmitters/chemicals such as substance P or glutamate (which are shown to accumulate at the site of local trauma), 31 and increased nocioceptor sensitivity secondary to inflammation. Furthermore, in any chronic painful condition, a cascade of events typically occurs, leading to a vicious cycle of pain maintenance. 32 These may include central sensitization after peripheral injury in which non-nociceptive spinal cord neurons perceive non-nociceptive peripheral stimuli as painful 31 and sympathetically maintained pain in which an overgrowth of sympathetic nerve fibers occurs in the dorsal root ganglia, resulting in persistent pain transmission. 14 The work from animal and human data demonstrates that BTX-A can affect each of the aforementioned mechanisms. First, both clinical and experimental data have shown that the introduction of BTX-A into a muscle results in transient loss of muscle volume via induction of muscle atrophy. 33 Considering our injection methodology, it is possible that the subsequent reduction of the size of the intrinsic foot muscles resulted in the relief of pressure on the neurovascular structures trapped under a tight and enlarged plantar fascia. Second, BTX-A has been shown to inhibit the release of substance P from dorsal root ganglia and to block the release of glutamate from synaptosomes. 12, 13 Third, pretreatment with BTX-A in rats results in a decreased local inflammatory response after the administration of formalin.
14 Fourth, intramuscular injection of BTX-A reduces the discharge of intrafusal muscle fibers, which normally convey large non-nociceptive input (reporting muscle length) to the spinal cord. 15 In chronic pain conditions (which may be the case in our subjects, who all complained of symptoms for Ͼ6 mos), reduction of this input theoretically can reduce the level of central sensitization. In animals, administration of BTX-A reduces the discharge of sympathetic neurons 16 and thus can reduce the role of the sympathetic system in pain maintenance.
Our injection technique aimed to treat both the plantar fascia and the underlying muscles (adductor hallucis, flexor digitorum brevis) in case both fascia and muscle contributed to the patients' pain. In the fascia, we hoped BTX-A would reduce inflammation, and in the underlying muscles, we hoped to see a positive effect on heel pain via muscle relaxation and loss of muscle volume. However, other suggested BTX-A actions (decreased central sensitization, decreased sympathetic activity, and reduced accumulation of substance P and glutamate) could have worked at the level of both structures. We believe our method of injection introduced BTX-A not only to the fascia but also into underlying muscles (flexor digitorum and abductor hallucis). In clinical practice, BTX-A injection into the arch of the foot with a 27-gauge, 0.75-inch needle often relieves painful flexor toe spasms in patients with stroke, head injury, cerebral palsy, and multiple sclerosis (our observations and others). We choose to treat preferentially the tender points in our patients because previous reports in myofascial pain syndromes have linked success in pain relief to this approach. 
FIGURE 4 Pressure algometry response values for the botulinum toxin A (BTX-A) and placebo groups.
Our study provided short-term results and, as in any short-term study, has limitations. Although most of our responders revisited us at 6 mos, only a few could be followed for 12 mos. This is due to the moving nature of our studied population (mostly young military soldiers) and the fact that the study was conducted at the time of a major military mobilization (2002) (2003) (2004) . Those who visited at 6 mos and a few who were seen at 12 mos had no recurrence of symptoms. Several subjects were able to return to full duty as military police or to return to activities such as bowling, tennis, and running. One patient was able to mow the lawn after an inability to conduct this chore for 10 yrs. A few subjects with bilateral plantar fasciitis requested that their placebo foot be injected with BTX-A. They also had similar results. These limited long-term results are encouraging but need to be reproduced in a prospective study with a larger number of patients. Due to the small number of patients at 6 and 12 mos, we could not conduct a valid statistical analysis for the long-term effect.
CONCLUSION
The results of our study demonstrate that the injection of BTX-A into the plantar region significantly improves the pain of recalcitrant plantar fasciitis at both 3 and 8 wks after treatment. Although the exact mechanism of action has not been elucidated, several theories have been presented in this article to explain the positive effect. Furthermore, blinded studies are necessary to confirm these results, which bear significant implications in caring for patients with this disorder. Long-term prospective studies are also necessary to show if these positive effects can be sustained with repeated treatments. Due to the high cost of BTX-A, the fiscal issues need to be evaluated in each patient individually. At the present time, treatment of plantar fasciitis with BTX-A should be considered for those patients in whom standard modes of treatment (many of them simple and inexpensive) have failed to provide pain relief.
